Please use this identifier to cite or link to this item:
https://repository.monashhealth.org/monashhealthjspui/handle/1/28932| Title: | Caution in expanding the use of abbreviated R-CHOP to poor-risk limited-stage DLBCL. | Authors: | Hawkes E.A.;Hertzberg M.;Opat S. | Institution: | (Hawkes) Department of Clinical Haematology and Medical Oncology, Olivia Newton-John Cancer Research Institute at Austin Health, Heidelberg, VIC, Australia (Opat) Clinical Haematology, School of Clinical Sciences at Monash Health, Monash University, Clayton, VIC, Australia (Hertzberg) Department of Haematology, Prince of Wales Hospital, University of New South Wales, Randwick, NSW, Australia | Issue Date: | 31-Dec-2020 | Copyright year: | 2020 | Publisher: | American Society of Clinical Oncology | Place of publication: | United States | Publication information: | Journal of Clinical Oncology. 38 (35) (pp 4221-4222), 2020. Date of Publication: 10 Dec 2020. | Journal: | Journal of Clinical Oncology | DOI: | http://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1200/JCO.20.02301 | PubMed URL: | 33104442 [http://www.ncbi.nlm.nih.gov/pubmed/?term=33104442] | ISSN: | 0732-183X | URI: | https://repository.monashhealth.org/monashhealthjspui/handle/1/28932 | Type: | Letter | Subjects: | clinical trial (topic) *diffuse large B cell lymphoma/dt [Drug Therapy] *diffuse large B cell lymphoma/rt [Radiotherapy] drug efficacy follow up functional status geriatric patient histopathology human International Prognostic Index letter clinical outcome overall survival patient safety positron emission tomography priority journal progression free survival proportional hazards model rare disease risk factor salvage therapy treatment duration multiple cycle treatment B cell lymphoma cancer prognosis cancer radiotherapy cancer recurrence *cancer staging cancer survival *cancer therapy chemoradiotherapy advanced cancer/dt [Drug Therapy] treatment response *cyclophosphamide plus doxorubicin plus prednisolone plus rituximab plus vincristine/dt [Drug Therapy] ibritumomab tiuxetan/dt [Drug Therapy] lactate dehydrogenase/ec [Endogenous Compound] rituximab/dt [Drug Therapy] rituximab/tm [Unexpected Outcome of Drug Treatment] Eastern Cooperative Oncology Group Performance Status age *cancer therapy advanced cancer / drug therapy age B cell lymphoma cancer prognosis cancer radiotherapy cancer recurrence *cancer staging cancer survival chemoradiotherapy clinical outcome clinical trial (topic) *diffuse large B cell lymphoma / *drug therapy / *radiotherapy drug efficacy follow up functional status geriatric patient histopathology human International Prognostic Index Letter multiple cycle treatment overall survival patient safety positron emission tomography priority journal progression free survival proportional hazards model rare disease risk factor salvage therapy treatment duration treatment response |
Type of Clinical Study or Trial: | Opinion, perspective or news |
| Appears in Collections: | Articles |
Show full item record
Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.